300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
CleanTech
Email
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Gaming
Health Care
Agriculture (AgTech)
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Mobile
Wellness
Education
Automotive
Hospitality
Biotechnology
Consumer
Sports
Legal
Software
Renewable Energy
eSports
Construction
Crowdfunding
Theatre
Medical
Venture Capital
Recruiting
Web3
Cannabis
LGBT
Fashion
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Social
Food and Beverage
Publishing
Music
Art
Beauty
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Infrastructure
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Mexico
Tajikistan
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
United Kingdom
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Angola
Europe
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Bangladesh
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Andreas Lindblom, EBAN Health Steering Committee at EIC

Andreas Lindblom

EBAN Health Steering Committee @ EIC

Stockholm, Sweden

Andreas Lindblom is a venture - series unknown investor at EIC in Stockholm focused on Health Care and Medical. Former CEO at Spring Securities, co-founder of Karolinska Center for Advanced Medical Simulation and Training, group manager at Sales & Service at Itivity, and physiotherapist at the Karolinska Institute. Andreas holds degrees in physics and physiotherapy.

Total investments:
13
Last investment:
Lead investor:
92%

Last updated:

Industries Andreas Lindblom invests in

Health CareMedicalBiotechnologyGeneticsPharmaceutical

Stages Andreas Lindblom invests in

Venture - Series UnknownSeries ASeries BEquity Crowdfunding

Countries Andreas Lindblom invests in

Sweden

Investment Focus

Industry

  • Health Care 5 (38%)
  • Medical 3 (23%)
  • Biotechnology 3 (23%)
  • Genetics 2 (15%)
  • Pharmaceutical 2 (15%)
See all 18 industries →

Stage

  • Venture - Series Unknown 5 (38%)
  • Series A 2 (15%)
  • Series B 1 (8%)
  • Equity Crowdfunding 1 (8%)

Investments

CompanyDescriptionRoundLinks
Everdrone Everdrone
Everdrone is at the forefront of a new era in public safety, where emergency drones are a critical and integrated part of everyday life. Our drones provide critical support to emergency response organisations by reaching incident scenes faster than any ground unit to gather vital information and deliver life-saving medical equipment. $3.9M / Venture - Series Unknown / Mar 19, 2026
NEOGAP Therapeutics NEOGAP Therapeutics
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. $9.8M / Venture - Series Unknown / Feb 11, 2026
TIRmed Pharma TIRmed Pharma
TIRmed Pharma develops drug candidates addressing major clinical needs. $4.7M / Venture - Series Unknown / Apr 09, 2025
PeptiSystems
PeptiSystems focuses on manufacturing and supplying instruments for the solid-phase synthesis of peptide and oligonucleotide therapeutics. $4.1M / Venture - Series Unknown / Dec 20, 2024
Capitainer Capitainer
Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. $1.4M / Series A / Feb 15, 2024
NEOGAP Therapeutics NEOGAP Therapeutics
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. $4.9M / Venture - Series Unknown / Nov 09, 2023
NEOGAP Therapeutics NEOGAP Therapeutics
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. $4.9M / Venture - Series Unknown / Nov 09, 2023
Capitainer Capitainer
Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. $5.8M / Series A / Apr 24, 2023
Encare Encare
Encare was established in 2009 to implement the ERAS Protocols on a global basis by- providing training to health care professionals on the ERAS Protocols- providing an interactive and web-based information system for evidence based - best practice management (EBM)The company has developed an interactive, user-friendly interface forthe collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence.The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings.Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States.The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery. $2.4M / Venture - Series Unknown / Sep 19, 2022
Capitainer Capitainer
Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. $3.5M / Series B / May 31, 2022
See all 13 investments →

Co-Investors

EIC

About EIC

VC Fund

European Innovation Council

EIC Contacts

NameEmailPhoneSocials
Ana Barjasic
Ana Barjasic Board Member
Andreas Lindblom
Andreas Lindblom EBAN Health Steering Committee
Brigitte Baumann
Brigitte Baumann President Emeritus
Candace Johnson
Candace Johnson President
Francoise Birnholz
Francoise Birnholz Affiliate Member

Sign up to unlock verified contacts

Unlock Contacts

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
CleanTech
Email
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Gaming
Health Care
Agriculture (AgTech)
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Mobile
Wellness
Education
Automotive
Hospitality
Biotechnology
Consumer
Sports
Legal
Software
Renewable Energy
eSports
Construction
Crowdfunding
Theatre
Medical
Venture Capital
Recruiting
Web3
Cannabis
LGBT
Fashion
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Social
Food and Beverage
Publishing
Music
Art
Beauty
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Infrastructure
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Mexico
Tajikistan
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Sudan
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Botswana
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United States
United Kingdom
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Angola
Europe
Cyprus
Qatar
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Bangladesh
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Andreas Lindblom invest in?

Andreas Lindblom invests primarily in Health Care, Medical and Biotechnology startups, most often at Venture - Series Unknown and Series A stage. Most of the 13 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Andreas Lindblom last invest?

The most recent investment recorded for Andreas Lindblom closed in Mar 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Andreas Lindblom Andreas Lindblom Find email